ATAI Life Sciences N.V (NASDAQ:ATAI) does about 1.95M shares in volume on a normal day but saw 6471963 shares change hands in the recent trading day. The company now has a market cap of 498.84M USD. Its current market price is $2.49, marking an increase of 7.79% compared to the previous close of $2.31. The 52 week high reached by this stock is $2.57 whilst the lowest price level in 52 weeks is $1.03. The script in recent trading has seen the stock touch a high of $5 and a low of $5.
1 analysts observing the ATAI Life Sciences N.V (ATAI) stock have set the 12-month price targets for the company’s shares at between $5 and $5. The consensus objective for the share price is $8.00, suggesting that the stock has a potential upside of 68.88% over the period. The median price target is 50.2% away from the current levels at $5.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 18, 2024 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $15 and $10. Maxim Group upgraded the stock to “Buy” from Hold on April 03, 2024 at a price target of $6. Loop Capital initiated its price target at $18.
The current price level is 37.91%, 58.41%, and 68.69% away from its SMA20, SMA50, and SMA200 respectively, with the ATAI price moving below the 50-day SMA on current market day. ATAI Life Sciences N.V (ATAI) stock is up 20.87% over the week and 69.39% over the past month. Its price is 87.22% year-to-date and 52.76% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.11 and -0.5 for whole year.
Its 12-month price target is $5. To reach the target analysts have set, the stock logically needs to grow 68.88 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.
Outstanding shares total 199.78M with insiders holding 8.26% of the shares and institutional holders owning 32.69% of the company’s common stock. The company has a return on investment of -77.36% and return on equity of -62.43%. The beta has a value of 1.48. Price to book ratio is 3.27 and price to sales ratio is 1511.64.
